Back to search
PIK3CA-Related Overgrowth Spectrum (PROS)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which PIK3CA-Related Overgrowth Spectrum (PROS) trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which PIK3CA-Related Overgrowth Spectrum (PROS) trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, zovegalisib (RLY-2608), in adults and chil…
This study is designed to demonstrate the efficacy and assess safety and tolerability of oral daily alpelisib in participants with PIK3CA-related overgrowth spe…
This study is a multi-center, open-label, single arm, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CYH33…
The purpose of this study is to provide post-trial access to alpelisib and to assess its long-term safety when administered as a single agent or in combination…
This is a prospective Phase II multi-center study with an initial 16-week, randomized, double-blind, placebo-controlled period, followed by two extension period…